DiaSorin SpA (DSRLF)
68.33
-0.88
(-1.27%)
USD |
OTCM |
Dec 09, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 3.686B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -36.38% |
| Valuation | |
| PE Ratio | 18.21 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 2.871 |
| Price to Book Value | 5.272 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 1.342 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 100.00% |
Profile
| DiaSorin SpA engages in developing, producing and marketing reagent kits for laboratory diagnostics. It operates through following segments Immunodiagnostics, Molecular Diagnostics, and Life Science. The Immunodiagnostics segment engages in the development of new tests based on complex algorithms. The Molecular Diagnostics segment focuses on providing specialty tests and complex multiplex solutions. The Life Science segment offers diagnostic instruments and technology. The firm provides clinical services in areas like Infectious diseases, bone and mineral, endocrinology, hypertension, oncology, stool diagnostics and autoimmunity. The company was founded in 1968 and is headquartered in Saluggia, Italy. |
| URL | http://www.diasorin.com/ |
| Investor Relations URL | N/A |
| HQ State/Province | Vercelli |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Next Earnings Release | Mar. 13, 2026 (est.) |
| Last Earnings Release | Nov. 05, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | May. 20, 2025 |
Ratings
Profile
| DiaSorin SpA engages in developing, producing and marketing reagent kits for laboratory diagnostics. It operates through following segments Immunodiagnostics, Molecular Diagnostics, and Life Science. The Immunodiagnostics segment engages in the development of new tests based on complex algorithms. The Molecular Diagnostics segment focuses on providing specialty tests and complex multiplex solutions. The Life Science segment offers diagnostic instruments and technology. The firm provides clinical services in areas like Infectious diseases, bone and mineral, endocrinology, hypertension, oncology, stool diagnostics and autoimmunity. The company was founded in 1968 and is headquartered in Saluggia, Italy. |
| URL | http://www.diasorin.com/ |
| Investor Relations URL | N/A |
| HQ State/Province | Vercelli |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Next Earnings Release | Mar. 13, 2026 (est.) |
| Last Earnings Release | Nov. 05, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | May. 20, 2025 |